Jaguar8 commented on a stock · Dec 9, 2024 08:55

NEWS SATURDAY

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

Y-mAbs Therapeutics (NASDAQ: YMAB)presented preclinical data and trial progress for its CD38-SADA platform at the 2024 ASH Annual Meeting. The preclinical data demonstrated selective binding and anti-tumor efficacy of CD38-SADA when used with Lutetium 177-DOTA in treating Non-Hodgkin Lymphoma (NHL).

The company also presented details of its ongoing Phase 1 Trial 1201, evaluating CD38-SADA PRIT with Lu177-DOTA in adults with relapsed or refractory NHL.

The trial consists of two parts: Part A focuses on dose escalation of CD38-SADA protein, while Part B aims to establish the optimal therapeutic dose of Lu177-DOTA. Both parts follow a 3+3 trial design with 4 planned dose levels.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

12K Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

9109

Followers

Following

109K

Visitors